BMRA BIOMERICA INC
Price Chart
Executive Summary
Biomerica entered into a Securities Purchase Agreement to sell its 6% stake (78,750 shares) in Diagnosis S.A. to buyers affiliated with CEO Zackary Irani for $500,000. The buyers paid via a secured promissory note that will be forgiven upon completion of the share transfer, which is subject to Polish regulatory approvals expected within 30 days. This is a related-party asset sale that converts a minority investment into cash for the company while creating a $500K secured debt obligation that converts to equity upon transfer.
Key Financial Metrics
Actionable Insight
Monitor the September 10, 2026 transfer deadline — if Polish regulatory approvals are not obtained by then, the $500K note becomes immediately due and payable, creating a cash liability for a company with a $7M market cap. The insider nature of the transaction (CEO is the lead buyer) warrants scrutiny of the Diagnosis S.A. stake's fair value.
Key Facts
- Biomerica sold 78,750 shares of Diagnosis S.A. (approx. 6% stake) for $500,000 to buyers including CEO Zackary Irani
- Buyers paid via a $500,000 secured promissory note bearing 8% interest, maturing in 12 months
- Note is forgivable upon completion of share transfer; transfer deadline is September 10, 2026
- Transfer requires Polish regulatory approvals expected within 30 days
- Diagnosis S.A. paid a $52,000 dividend to Biomerica in 2026, which was factored into the purchase price
- The buyers are insiders: CEO Zackary Irani ($300,000), AVR August LLC ($100,000), AVR September LLC ($100,000)
Financial Impact
Biomerica receives $500,000 cash for a non-core minority stake, representing a 6% position in a Polish diagnostics company. The company also received a $52,000 dividend from Diagnosis in 2026.
Risk Factors
- Transfer may fail to close by September 10, 2026, triggering immediate repayment of the $500K note
- Polish regulatory approval is a condition to closing and may be delayed or denied
- Related-party transaction with CEO raises governance questions about asset valuation
- The $500K represents ~7% of Biomerica's market cap, material for a micro-cap company
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027290 |
| Document: form8-k.htm | 0001493152-26-027290 |
| Document: 0001493152-26-027290-index-headers.html | 0001493152-26-027290 |
| Document: 0001493152-26-027290-index.html | 0001493152-26-027290 |
| Document: 0001493152-26-027290.txt | 0001493152-26-027290 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
8d ago
|
8-K
| $2.32 awaiting T+5 | awaiting T+5 | — | $2.05 (−11.64%) |
|
May 28, 2026
15d ago
|
Press Release
| $2.43 $2.11 | ▼ −13.17% | ▼ −13.12% | $2.05 (−15.64%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $2.10 $2.16 | ▲ +2.86% | ▲ +1.46% | $2.05 (−2.38%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $2.10 $2.16 | ▲ +2.86% | ▲ +1.46% | $2.05 (−2.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access